Several agents including Ipilimumab (anti-CTLA-4) and Nivolumab (anti-PD-1) are effective in the management of patients with melanoma, small cell and non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC), and are FDA-approved first-line treatments for patients with advanced disease (4, 5). The gene discussed is CTLA4; the disease is renal cell carcinoma.